Which BP Drugs Reverse Aortic Stiffness—and Which Make It Worse

The Arterial Stiffness Series – Part 3

🎧 ▶️ Press the play button below to listen.

This article focuses on aortic stiffness. The stiffness of your aorta, the massive elastic tube leaving your heart. This is the gold-standard measurement for cardiovascular risk (carotid-femoral PWV). When we say ‘arterial stiffness’ in this series, the aorta is what matters most.

Introduction

You take your blood pressure at home. The cuff reads 128/78. Normal, right? Your doctor nods approvingly. Your heart, they say, is protected.

But what if that number is a lie?

Not a deliberate lie. A mechanical lie. The brachial cuff measures pressure in your arm—the muscular, forgiving, relatively stiff vessels of your periphery. Meanwhile, your aorta—the massive elastic tube leaving your heart—may be aging into leather behind the scenes.

Here is the uncomfortable truth: Two patients with identical cuff pressures can have radically different aortic stiffness. And different blood pressure drugs affect that stiffness in opposite ways.

Some drugs lower the number on the cuff while doing nothing, or worse, accelerating damage to your aortic wall. Others lower pressure and actively reverse collagen deposition, suppress MMP-9, and restore elasticity.

This article names names. It categorizes antihypertensives not by their ability to move a mercury column, but by their effect on vascular biology. Because the goal is not a lower number. The goal is a rubber aorta, not a leather one.

---

I. The Distinction – Brachial vs. Central Pressure

Before we discuss drugs, you need to understand one concept: the difference between brachial and central blood pressure.

Measurement	What It Measures	Why It Matters
Brachial BP (standard arm cuff)	Pressure in the muscular arteries of your arm	Easy to measure; familiar to doctors
Central BP (aortic BP)	Pressure in your aorta, closest to heart and brain	Stronger predictor of heart attack, stroke, and death

Here is the catch: Brachial BP and central BP are not always the same. In young, healthy arteries, they track closely. In stiffened, older arteries, central BP can be 10–20 mmHg higher than brachial BP—even when the arm cuff reads “normal.”

This is called amplification, and it disappears as arteries stiffen. Some drugs lower brachial BP more than central BP. Others do the opposite.

The best drugs for arterial stiffness lower both, but preferentially lower central BP and directly remodel the aortic wall.

---

II. The Winners – ACE Inhibitors and ARBs

The Mechanism: Blocking Angiotensin II

Angiotensin II is a powerful vasoconstrictor. It raises blood pressure by squeezing your arteries. But it does something else: it directly promotes collagen deposition in the aortic wall.

Think of angiotensin II as a construction foreman for scar tissue. When it is active, your body lays down more collagen in the elastin-rich media of your aorta—the very process of stiffening you learned about in Part 1.

ACE inhibitors (lisinopril, ramipril, perindopril) block the enzyme that produces angiotensin II. 

ARBs (losartan, telmisartan, valsartan) block the angiotensin II receptor. Both interrupt the pro-stiffening signal.

The Evidence

Drug Class	Effect on PWV	Mechanism
ACE inhibitors	Reduces PWV by 0.5–1.5 m/s	Lowers pressure + reduces collagen deposition
ARBs	Reduces PWV by 0.5–1.5 m/s	Lowers pressure + reduces collagen deposition + may regress existing fibrosis

A meta-analysis of 27 trials found that ACE inhibitors and ARBs consistently reduce PWV more than other drug classes at equivalent reductions in blood pressure. This is the blood pressure-independent effect—they improve stiffness beyond what you would expect from the number on the cuff.

📖 Quick Definition: What Is PWV?

Pulse Wave Velocity (PWV) measures how fast the pressure wave from your heartbeat travels down your aorta.

PWV (m/s)	Meaning
5–6	Excellent (young, supple aorta)
7–8	Borderline (mild stiffening)
8–10	Moderate stiffening
>10	Severe stiffening (leather pipe)

Lower is better. Each 1 m/s increase = roughly 10–15% higher cardiovascular risk.

If you read Part 1 of this series, Why Mild Hypertension and Insulin Resistance May Be Damaging Your Arteries Right Now you have already seen this. For new readers, this is the number that matters most for your arterial health.

The Standouts: Telmisartan and Losartan

Not all ARBs are equal. Telmisartan and losartan have unique properties:

Drug	Unique Mechanism	Evidence
Telmisartan	Partial PPAR-γ agonist (similar to some diabetes drugs)	Reduces MMP-9 activity and C-reactive protein more than other ARBs
Losartan	Blocks the AT1 receptor while leaving AT2 receptor intact	May promote beneficial vascular remodeling

Practical takeaway: If your doctor prescribes an ACE inhibitor or ARB, you are already on one of the best drug classes for arterial stiffness. Telmisartan and losartan have the most supportive data specifically for PWV reduction.

---

III. The Problem with Traditional Beta-Blockers

Beta-blockers (atenolol, metoprolol, propranolol) lower blood pressure by slowing your heart rate and reducing cardiac output. They are excellent for angina, heart failure, and certain arrhythmias.

But for isolated hypertension (high blood pressure without these other conditions), traditional beta-blockers are now second-line drugs according to major guidelines (ESC, JNC, NICE). Here is why.

The Wave Reflection Problem

When your heart beats, the pressure wave travels down your aorta. At branch points, part of that wave reflects back toward your heart. In a young, flexible artery, that reflected wave returns after the heart has finished ejecting blood — it arrives during relaxation, where it actually helps coronary blood flow.

When you take a traditional beta-blocker, your heart rate slows. The time between beats lengthens. The reflected wave now returns while the heart is still ejecting — arriving during systole. This augments central aortic pressure even as the brachial cuff shows a lower number.

Think of it like a crowded subway platform. If you slow the train schedule (lower heart rate), more people accumulate on the platform (wave reflection), and the next person to board gets pushed harder.

The Landmark Study: CAFE (2006)

The CAFE study (Conduit Artery Function Evaluation) was a substudy of the ASCOT trial — one of the largest hypertension trials ever conducted. It compared:

• Atenolol-based therapy (traditional beta-blocker ± diuretic)
• Amlodipine-based therapy (calcium channel blocker ± perindopril, an ACE inhibitor)

Despite identical brachial blood pressure reductions between the two groups, the atenolol-based group had significantly higher central aortic pressure and higher augmentation index (a measure of wave reflection). This difference in central pressure is thought to explain why atenolol-based therapy did not reduce cardiovascular events as much as amlodipine-based therapy.

Key takeaway: Two drugs can lower the arm cuff equally, but their effects on your aorta can be radically different.

What Traditional Beta-Blockers Do (and Do Not Do)

Drug	Effect on Brachial BP	Effect on Central BP & Augmentation Index	Effect on PWV
Atenolol	Lowers	Less effective than other drug classes; may increase augmentation index	Reduces (but less than ACE inhibitors)
Metoprolol	Lowers	Neutral or slightly less effective than nebivolol	Generally neutral

A Note on Heart Rate Independence

Some researchers have asked: is the problem purely the slower heart rate? The answer appears to be no. Ivabradine — a drug that lowers heart rate without affecting the blood vessel wall — does not worsen central blood pressure in the same way. This suggests traditional beta-blockers have additional vascular effects (perhaps on arterial stiffness directly) beyond their heart rate slowing.

Age-Dependent Nuance

Not all patients with hypertension are the same. In young or middle-aged patients with sympathetic overactivity (fast heart rate, high cardiac output, anxiety-driven hypertension), traditional beta-blockers may still be a reasonable first-line choice. The guidelines’ downgrade applies primarily to isolated hypertension in older adults, where the hemodynamic profile is different.

---

IV. The Exception – Nebivolol (The Best Beta-Blocker for Central Hemodynamics)

Nebivolol is a third-generation beta-blocker with a unique property: it increases nitric oxide (NO) bioavailability, leading to peripheral vasodilation.

How Nebivolol Works

Nebivolol is primarily a highly selective beta-1 blocker (like metoprolol). But it has an additional effect: it stimulates endothelial nitric oxide synthase (eNOS) , increasing NO production. The exact mechanism is debated — some studies point to beta-3 receptor stimulation, others to other endothelium-dependent pathways — but the clinical effect is clear: nebivolol causes peripheral vasodilation, which reduces wave reflection and lowers central aortic pressure.

What the Evidence Shows: The Kampus et al. (2011) Trial

A randomized, double-blind study followed 80 patients with moderate hypertension for one year, comparing nebivolol (5 mg daily) to metoprolol succinate (50–100 mg daily).

Key findings:

Outcome	Nebivolol	Metoprolol
Heart rate reduction	✅ Yes	✅ Yes (equivalent)
Brachial BP reduction	✅ Yes	✅ Yes (equivalent)
Central systolic BP reduction	✅ Yes (significant)	❌ No
Central diastolic BP reduction	✅ Yes (significant)	❌ No
Central pulse pressure reduction	✅ Yes (significant)	❌ No
Left ventricular wall thickness reduction	✅ Yes (significant)	❌ No
Augmentation index change	❌ No significant change	❌ No significant change
Carotid-femoral PWV change	❌ No significant change	❌ No significant change

Source: Kampus et al., Hypertension, 2011.

What this means:

• Nebivolol is superior to metoprolol for central blood pressure and left ventricular remodeling.
• However, neither drug significantly changed PWV after one year.
• The claim that “nebivolol improves PWV” is not supported by this trial. Nebivolol’s advantage is in central BP and wave reflection, not directly in PWV.

Practical Takeaway

If you need a beta-blocker for…	Recommendation
Hypertension alone (no other indication)	Nebivolol is preferred if a beta-blocker is necessary. But ACE inhibitors, ARBs, or CCBs are usually better first-line choices.
Heart failure with reduced ejection fraction (HFrEF)	Carvedilol, metoprolol succinate, or bisoprolol are guideline-recommended. Nebivolol is also approved but less studied.
Angina or post-myocardial infarction	Traditional beta-blockers are well-supported. Nebivolol is a reasonable alternative but not first-line.

---

V. The Illusion – Amlodipine (Calcium Channel Blockers)

What Amlodipine Does Well

Amlodipine is a dihydropyridine calcium channel blocker (CCB). It lowers blood pressure by relaxing the smooth muscle in artery walls. It is effective, well-tolerated, and among the most prescribed antihypertensives worldwide.

It lowers brachial BP very well.

What Amlodipine Does Not Do

Here is the nuance: amlodipine has minimal effect on central aortic stiffness beyond what you would expect from the pressure reduction alone.

Comparison	Effect on Brachial BP	Effect on Central PWV
Amlodipine vs. placebo	Significant reduction	Reduction proportional to BP change (no additional benefit)
ACE inhibitor vs. amlodipine	Similar reduction	ACE inhibitor reduces PWV more (BP-independent effect)

A direct comparison trial found that ramipril (an ACE inhibitor) and amlodipine lowered brachial BP equally. But ramipril lowered central PWV significantly more—because ramipril reduced collagen deposition, while amlodipine only relaxed smooth muscle.

Practical takeaway: Amlodipine is not a bad drug. It lowers pressure, and lowering pressure is good. But if your primary goal is to reverse or slow arterial stiffness, an ACE inhibitor or ARB is a better choice. Amlodipine is an excellent add-on drug if your BP remains high despite an ACE inhibitor or ARB.

---

VI. The Crossover – SGLT2 Inhibitors (Diabetes Drugs That Reduce Stiffness)

What Are SGLT2 Inhibitors?

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) were developed for type 2 diabetes. They work by blocking glucose reabsorption in the kidneys, causing you to excrete sugar in your urine.

But something unexpected happened in clinical trials: patients on SGLT2 inhibitors had dramatic reductions in heart failure hospitalizations and cardiovascular death—even in people without diabetes.

Why SGLT2 Inhibitors Reduce Arterial Stiffness

The mechanisms are multiple and still being studied, but here is what we know:

Mechanism	How It Helps
Reduced volume load	Excreting glucose pulls water with it, lowering BP
Reduced AGE formation	Lower blood glucose → fewer new AGE cross-links on elastin
Reduced inflammation	SGLT2 inhibitors lower IL-6 and TNF-α
Improved endothelial function	Increased nitric oxide bioavailability
Reduced aortic wall stress	Lower pulse pressure and better wave reflection

The evidence: In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced PWV by 0.6–1.0 m/s compared to placebo over 6–12 months. The effect appears to be partially independent of blood pressure.

Relevance for Non-Diabetics

SGLT2 inhibitors are now FDA-approved for heart failure with reduced ejection fraction and chronic kidney disease in non-diabetics. For arterial stiffness specifically, data in non-diabetic populations are emerging but promising.

Practical takeaway: If you have insulin resistance, prediabetes, or type 2 diabetes and elevated PWV, an SGLT2 inhibitor may be the most powerful drug you can take—not just for glucose, but for your aorta. This is a conversation to have with your doctor, especially if you are already on metformin or other diabetes drugs.

---

Conclusion: The Takeaway

• Not all blood pressure drugs are equal for arterial stiffness. Some lower the cuff number while doing less to protect your aorta.
• ACE inhibitors and ARBs are the winners for arterial stiffness. They lower central BP and directly reduce collagen deposition. Telmisartan and losartan have strong data.
• Traditional beta-blockers (atenolol, metoprolol) are second-line for isolated hypertension. They lower brachial BP but underperform other drug classes on central aortic pressure. However, they are not “worse than no treatment” — that claim is not supported by evidence.
• The CAFE study (2006) is the landmark trial. It showed that atenolol-based therapy had higher central aortic pressure than amlodipine-based therapy, despite identical brachial BP reduction.
• If you need a beta-blocker, nebivolol is the best choice for central hemodynamics. It lowers central BP and improves wave reflection through NO-mediated vasodilation. However, its effect on PWV is less clear — in head-to-head trials, neither nebivolol nor metoprolol significantly changed PWV after one year.
• Amlodipine lowers brachial BP effectively but has minimal additional PWV benefit beyond pressure reduction. It is an excellent add-on drug.
• SGLT2 inhibitors reduce arterial stiffness in insulin-resistant patients through multiple pathways: lower volume, lower glucose (fewer AGEs), and reduced inflammation.
• Age and patient context matter. In young patients with sympathetic overactivity, traditional beta-blockers may still be reasonable. The guidelines’ downgrade applies primarily to older adults with isolated hypertension.
• Do not stop a beta-blocker abruptly. Withdrawal must be gradual under medical supervision.
• The goal is not a lower cuff number alone. The goal is a rubber aorta, not a leather one.

Important Safety Disclaimer

⚠️ Do not change, stop, or adjust your blood pressure medications based on this article.

All antihypertensive drugs have side effects and risks. The “best” drug for arterial stiffness may not be the safest or most appropriate for your specific medical history, kidney function, electrolyte levels, or other medications.

Do not stop a beta-blocker abruptly — this can cause dangerous rebound hypertension, heart rate spikes, and risk of heart attack or stroke. Beta-blocker withdrawal must be done gradually under medical supervision.

This article is educational, not medical advice.

Coming next in The Arterial Stiffness Series:

Can You Measure PWV at Home? (Yes, No, and What to Actually Buy)

You have now read about the two-hit model, the evidence for SAC, and which blood pressure drugs help or harm your aorta.

But one question is probably nagging at you:

“How do I know if any of this is actually working for ME?”

Do you need to go to a special clinic? Can your smartwatch tell you? Is there a scale that measures arterial stiffness? What about those apps that claim to measure “vascular age” from your fingertip?

No hype. No fake “vascular age” apps. Just a practical protocol for the motivated.

Because if you cannot measure it, you cannot manage it.

Part 4 coming next.

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.

Related:

1. Why Mild Hypertension and Insulin Resistance May Be Damaging Your Arteries Right Now
2. Garlic’s Hidden Molecule: How S-Allylcysteine (SAC) and Black Garlic Protect the Artery That Won’t Heal Itself
3. Machine Learning Finds Your Hidden Heart Disease Risks
4. ApoB Reveals Hidden Heart Disease And Diabetes Risk Early
5. How to Interpret ApoB and ApoA1 Results
6. ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
7. CAC And CTA Scans Help Detect Heart Disease Early
8. ApoB and ApoA1 Best Predict Heart Attack: How To Get Tested
9. ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
10. Heart Attack Risk? Use The Framingham Risk Calculator And Lower It Now!
11. Discover Your Cardiac Age with This Free Calculator
12. Heart Rate Recovery Reveals Hidden Secrets About Your Heart
13. Drink Coffee At This Time To Slash Heart Attack Risk
14. The FODMAP Trap That Mimics Heart Attacks During Exercise
15. The Hidden Link Between High Blood Sugar and Heart Attacks
16. Strep From the Mouth and Blood and Sudden Cardiac Death — What You Need to Know
17. Lithium’s Hidden Power: Unlocking Protection Against Cardiovascular Disease
18. How Reduced Blood Sugar Lowers BP And Cardiovascular Risks
19. Cholesterol and Blood Sugar: The Strong Link

References:

1. Williams, B., et al. (2006). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113(9), 1213–1225.
2. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012 Mar;221(1):18-33. doi: 10.1016/j.atherosclerosis.2011.12.005. Epub 2011 Dec 9. PMID: 22209214.
3. Peng, F., Pan, H., Wang, B. et al. The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis. Hypertens Res 38, 613–620 (2015). https://doi.org/10.1038/hr.2015.51
4. Kampus, P., Serg, M., Kals, J., et al. (2011). Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension, 57(6), 1122–1128.
5. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011 Jun;57(6):1122-8. doi: 10.1161/HYPERTENSIONAHA.110.155507. Epub 2011 May 2. PMID: 21536983.
6. Redón, J., Pascual-Izuel, J. M., Rodilla, E., Vicente, A., Oliván, J., Bonet, J., … Almirall, J. (2014). Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study. Blood Pressure, 23(3), 181–188. https://doi.org/10.3109/08037051.2013.840421

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases